Targeted Disease(s):
COPD
Purpose of Study:
Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD
Study Dates:
December 16, 2020 - November 28, 2025
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Sanofi and Regeneron
Sponsors:
Sanofi
Contact:
Phone: 800-633-1610, option 6
Email: Contact-US@sanofi.com
ClinicalTrails.gov Identifier:
NCT04701983
